A proprietary transdermal delivery system utilizing sufentanil, a potent opioid, for the treatment of chronic pain.
View complete product pipeline
October 27, 2014DURECT Provides Update on REMOXY® and POSIDUR™ Programs
October 24, 2014DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call
October 10, 2014DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentation at the American Society of Anesthesiologists Annual Meeting
August 25, 2014DURECT to Present at the Rodman & Renshaw Investment Conference